

1 Supplementary information

2 **Isolation, chemical profile and antimalarial activities**
 3 **of bioactive compounds from *Rauvolfia caffra* Sond**

4 Dorcas B Tlhapi ¹, Isaiah D.I Ramaite ^{1,*}, Teunis van Ree ¹, Chinedu P Anokwuru ¹, Tagliatela-
 5 Scafati Orazio ² and Heinrich C Hoppe ³

6 ¹ Department of Chemistry, University of Venda, Thohoyandou, Private Bag X5050, 0950, South Africa;
 7 dorcastlhapi@gmail.com; Isaiah.Ramaite@univen.ac.za; Teuns.VanRee@univen.ac.za, ,
 8 anokwuruchi@gmail.com


9 ² Department of Pharmacy, University of Naples Federico II Via D. Montesano 49, 1-80131, Napoli (Italy);
 10 scatagli@unina.it

11 ³ Department of Biochemistry and Microbiology, Rhodes University, Grahamstown, 6140 South Africa;
 12 H.Hoppe@ru.ac.za

13 * Correspondence: Isaiah.Ramaite@univen.ac.za; Tel.: +27(0)15-962-8262

14 Academic Editors:

15 Received: date; Accepted: date; Published: date




16

17


Figure S1. UPLC-MS of the crude extract.

18




19
20

Figure S2. UPLC-MS of Fraction F3.



21
22
23


Figure S3. UPLC-MS of Fraction F5.



24

25


26

Figure S4. Expanded $^1\text{H-NMR}$ spectrum of lupeol (1).

27

28


Figure S5. Expanded $^1\text{H-NMR}$ spectrum of lupeol (1).



29

30


31

Figure S6. ^{13}C -NMR spectrum of lupeol (1).

32

33


Figure S7. ^{13}C -NMR spectrum of lupeol (1).



34

35

36


Figure S8. ^{13}C -NMR spectrum of lupeol (1).(16S,17R,19E)-21 α -(β -D-glucopyranosyloxy)-1,2-didehydro-2,7-dihydro-7 β ,17-cyclosarpagan-17-yl acetate

37

38


39

Figure S9. Mass spectrum of raucaffricine (2).



40

41


Figure S10. ^{13}C -NMR spectrum of raucaffricine (2).

42

43


44

Figure S11. IR spectrum of raucaffricine (2).

(16S,17R,19E)-21 α -(β -D-glucopyranosyloxy)-1,2-didehydro-2,7-dihydro-7 β ,17-cyclosarpagan-17-yl acetate

45

46


Figure S12. Expanded ^1H -NMR spectrum of raucaffricine (2).(16S,17R,19E)-21 α -(β -D-glucopyranosyloxy)-1,2-didehydro-2,7-dihydro-7 β ,17-cyclosarpagan-17-yl acetate

47

48

49


Figure S13. Expanded ^1H -NMR spectrum of raucaffricine (2).

(16*S*,17*R*,19*E*)-21 α -(β -D-glucopyranosyloxy)-1,2-didehydro-2,7-dihydro-7 β ,17-cyclosarpagan-17-yl acetate

50

51


52

Figure S14. Expanded $^1\text{H-NMR}$ spectrum of raucaffricine (2).

53


54

Figure S15. IR spectrum of *N*-methylsarpagine (3).



55

56


Figure S16. Expanded ^1H -NMR spectrum of *N*-methylsarpagine (3).

57

58

59

Figure S17. Expanded ^1H -NMR spectrum of *N*-methylsarpagine (3).




60

61

62

Figure S18. ¹³C-NMR spectrum of *N*-methylsarpagine (3).

(15 α , 19E)-10,17-Dihydroxy-4-methylsarpagan-4-ium




63

64

65

Figure S19. Mass spectrum of spigatrine (4).




66

67

Figure S20. IR spectrum of spogatrine (4).


68



69


70

Figure S21. Expanded ^1H -NMR spectrum of spogatrine (4).



71

72

Figure S22. Expanded ¹H-NMR spectrum of spogatrine (4).

73

74

75

Figure S23. ¹³C-NMR spectrum of spogatrine (4).